Context Therapeutics Inc. (CNTX)
(Delayed Data from NSDQ)
$1.86 USD
-0.10 (-5.10%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $1.86 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Context Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 14 | 36 | 50 | 0 | -99,999 |
Receivables | 0 | 0 | 0 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 2 | 2 | 2 | 0 | NA |
Total Current Assets | 16 | 38 | 51 | 0 | NA |
Net Property & Equipment | 0 | 0 | 0 | 0 | NA |
Investments & Advances | 0 | 0 | 0 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 0 | 0 | 0 | 0 | NA |
Total Assets | 16 | 38 | 51 | 0 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 2 | 1 | 2 | 3 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 6 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 2 | 2 | 1 | 1 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 0 | 0 | 0 | 0 | NA |
Total Current Liabilities | 4 | 3 | 3 | 10 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 8 | NA |
Total Liabilities | 4 | 3 | 3 | 17 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 80 | 79 | 78 | 2 | NA |
Retained Earnings | -68 | -44 | -29 | -19 | NA |
Other Equity | 0 | 0 | 0 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 12 | 35 | 48 | -17 | NA |
Total Liabilities & Shareholder's Equity | 16 | 38 | 51 | 0 | NA |
Total Common Equity | 12 | 35 | 48 | -17 | 0 |
Shares Outstanding | 15.90 | 15.90 | 15.90 | NA | NA |
Book Value Per Share | 0.75 | 2.19 | 3.04 | 0.00 | 0.00 |
Fiscal Year End for Context Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 102 | 10 | 14 | 22 | 25 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 2 | 1 | 3 |
Total Current Assets | 103 | 11 | 16 | 23 | 28 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 103 | 11 | 16 | 23 | 28 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 2 | 2 | 2 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 1 | 1 | 2 | 3 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 2 | 3 | 4 | 5 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2 | 3 | 4 | 5 | 4 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 175 | 80 | 80 | 80 | 79 |
Retained Earnings | -74 | -72 | -68 | -61 | -55 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 101 | 8 | 12 | 18 | 24 |
Total Liabilities & Shareholder's Equity | 103 | 11 | 16 | 23 | 28 |
Total Common Equity | 101 | 8 | 12 | 18 | 24 |
Shares Outstanding | 75.00 | 15.90 | 15.90 | 15.90 | 15.90 |
Book Value Per Share | 1.35 | 0.53 | 0.75 | 1.16 | 1.51 |